You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
常山藥業(300255.SZ):艾本那肽啟動Ⅲ期臨牀試驗
格隆匯 05-12 16:04

格隆匯5月12日丨常山藥業(300255.SZ)公佈,公司和控股子公司常山凱捷健生物藥物研發(河北)有限公司於2015年4月收到國家食品藥品監督管理總局簽發的藥物臨牀試驗批件及審批意見通知件,批准公司申報的艾本那肽原料藥和艾本那肽注射液進行Ⅰ/Ⅱ/Ⅲ期臨牀試驗。

公司已經完成了艾本那肽注射液Ⅱ期臨牀研究相關工作和Ⅲ期臨牀試驗的準備工作。根據艾本那肽注射液前期臨牀試驗結果及臨牀試驗批件要求,結合公司實際情況,公司認為已經具備啟動Ⅲ期臨牀試驗的條件,決定啟動Ⅲ期臨牀試驗。

艾本那肽是治療II型糖尿病的1.1類藥物,是長效GLP-1受體激動劑製劑,可一週注射一次,極大地提高了患者的用藥依從性。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account